Active substanceAcetylsalicylic acidAcetylsalicylic acid
Similar drugsTo uncover
  • ASA cardio®
    pills inwards 
    MEDISORB, CJSC     Russia
  • Aspicor®
    pills inwards 
    VERTEKS, AO     Russia
  • Aspinate®
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Aspinate® 300
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Aspinate® Cardio
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Aspirin®
    pills inwards 
    Bayer Konsyumer Kare AG     Switzerland
  • Aspirin® Cardio
    pills inwards 
    Bayer Konsyumer Kare AG     Switzerland
  • Aspirin® Express
    pills inwards 
    BAYER, AO     Russia
  • Acecardol®
    pills inwards 
  • Acetylsalicylic acid
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Acetylsalicylic acid
    pills inwards 
    ATOLL, LLC     Russia
  • Acetylsalicylic acid
    pills inwards 
    MARBIOFARM, OJSC     Russia
  • Acetylsalicylic acid
    pills inwards 
  • Acetylsalicylic acid
    pills inwards 
    PHARMACY 36.6, CJSC     Russia
  • Acetylsalicylic acid
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Acetylsalicylic acid
    pills inwards 
  • Acetylsalicylic acid
    pills inwards 
  • Acetylsalicylic acid
    pills inwards 
  • Acetylsalicylic acid
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Acetylsalicylic acid
    pills inwards 
  • Acetylsalicylic acid
    pills inwards 
  •    
  • Acetylsalicylic acid "York"
    pills inwards 
  • Acetylsalicylic acid
    capsules inwards 
  • Acetylsalicylic acid MS
    pills inwards 
    MEDISORB, CJSC     Russia
  • Acetylsalicylic acid-Lect
    pills inwards 
  • Acetylsalicylic acid-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • ASFARMA, LLC     Russia
  • Cardiasca®
    pills inwards 
  • Sanovas®
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Taspir
    pills inwards 
  • Trombo ACC®
    pills inwards 
    VALEANT, LLC     Russia
  • Thrombogard 100
    pills inwards 
    Adifarm, EAD     Bulgaria
  • Thrombopol®
    pills inwards 
  • Uppsarin UPSA®
    pills inwards 
  • Dosage form: & nbsptablets, effervescent
    Composition:

    Active substance: acetylsalicylic acid 500 mg,

    Excipients: sodium hydrogen carbonate 1100.0 mg; citric acid anhydrous - 430,0 mg; sodium citrate anhydrous 530.0 mg; sodium carbonate anhydrous 71.5 mg; aspartame - 10,0 mg; povidone 1.0 mg; crospovidone 5.0 mg; flavoring orange * 2.5 mg.

    *- the fragrance includes: aromatic components: α-pinene, β-pinene, myrcene, limonene, octanal, decanal, linalool, α-terpineol; non-aromatic components: maltodecstrands, acacia gum (E414), sulfur dioxide (E220), butylhydroxyanisole (E320).

    Description:Round, flat with beveled edges and risky on one side white tablets. When dissolved in water, bubbles of gas are observed.
    Pharmacotherapeutic group:Non-steroidal anti-inflammatory drug (NSAID).
    ATX: & nbsp

    N.02.B.A   Salicylic acid and its derivatives

    Pharmacodynamics:

    Has anti-inflammatory, analgesic and antipyretic effects associated with the suppression of cyclooxygenase 1 and 2, regulating the synthesis of prostaglandins.Reduces aggregation, platelet adhesiveness and thrombus formation by suppressing the synthesis of thromboxane A2 in platelets. Antiaggregation effect persists for 7 days after a single dose (more pronounced in men than in women).

    Pharmacokinetics:

    - Suction:

    Dissolved in water, the drug Upsarin Upsa® tablet forms a buffer solution, which, after taking the drug maintains active substances in dissolved form, preventing them from contact with the acidic environment of the stomach to move back in undissolved form and precipitate as solids on its walls. The result is more rapid and complete absorption of the drug as well as its better tolerability in comparison with conventional tablets acetylsalicylic acid. The maximum concentration of the drug in the plasma is reached after 15-40 minutes. Bioavailability of acetylsalicylic acid varies depending on the received dose: about 60% - to less than 500 mg dose and 90% for doses greater than 1 g due to saturation of the reaction of hydrolysis in the liver. Acetylsalicylic acid undergoes rapid hydrolysis with the formation of an active metabolite - salicylic acid.


    - distribution:

    Acetylsalicylic and salicylic acids are intensively distributed in tissues; they penetrate the placental barrier and are found in the mother's milk.
    At a therapeutic concentration, about 90% of salicylic acid binds to serum proteins.


    - metabolism and excretion:

    Acetylsalicylic acid is extensively metabolized in the liver.

    It is excreted mainly with urine in the form of salicylic acid and conjugates with glucuronic acid, as well as in the form of salicylic urinary and gentesic acid.

    The half-life is 15-20 minutes for acetylsalicylic acid and 2 - 4 hours for salicylic acid.

    Indications:

    Symptomatic treatment in adults with moderate or mild pain syndrome of various origins: headache (including associated with alcohol withdrawal syndrome), toothache, migraine, neuralgia, thoracic radicular syndrome, muscle and joint pain, algodismenorrhea (pain in menstruation).

    Elevated body temperature for colds and other infectious and inflammatory diseases in adults and children over 15 years of age.

    Contraindications:

    - children's age till 15 years;

    - hypersensitivity to acetylsalicylic acid, other NSAIDs and components of the drug;

    - deficiency of glucose-6-phosphate dehydrogenase, phenylketonuria (the preparation contains aspartame);

    - The bronchial asthma induced by reception of salicylates and other NSAIDs in the anamnesis; pregnancy (I and III trimester), the period of breastfeeding;

    - erosive and ulcerative lesions of the gastrointestinal tract (in the phase of exacerbation), gastrointestinal bleeding;

    - hemorrhagic diathesis (hemophilia, von Willebrand's disease, telangiectasia, hypoprothrombinemia, thrombocytopenia, thrombocytopenic purpura); marked violations of the liver or kidneys;

    - deficiency of vitamin K;

    - glucose-galactose malabsorption;

    - simultaneous administration with methotrexate at a dose of 15 mg / week or more (see section "Interaction");

    - simultaneous reception of oral anticoagulants and acetylsalicylic acid in a dose exceeding 3 g per day (see section: "Interaction").

    If you have any of the listed diseases, always consult a doctor before using the drug.

    Carefully:

    Hyperuricemia, urate nephrolithiasis, gout,stomach and / or duodenal ulcer or gastrointestinal hemorrhage (in history), renal and hepatic insufficiency, bronchial asthma, polyposis of the nose, drug allergy, pregnancy (trimester), simultaneous reception of anticoagulants and acetylsalicylic acid in a dose of less than 3 g in day, simultaneous intake of acetylsalicylic acid and methotrexate in a dose of less than 15 mg / day, metrorrhagia (acyclic uterine bleeding), hypermenorrhea (profuse and prolonged menstruation).

    If you have any of the listed diseases, always consult a doctor before using the drug.

    Pregnancy and lactation:

    The drug Uppsarin Uppsa® is contraindicated in the first and third trimester of pregnancy.

    Use in the second trimester of pregnancy - with caution, only if the potential use of the application exceeds the potential risk to the fetus.

    Breastfeeding when using the drug is not recommended.

    Dosing and Administration:

    Mode of application: take after eating, dissolving the tablet / tablet in 100-200 ml of water.

    Regular adherence to the regimen allows you to avoid a sharp increase in temperature and reduce the intensity of the pain syndrome.

    Adults and children over 15 years of age:

    1 tablet (500 mg) per reception up to 6 times a day.

    With severe pain and high temperature - 2 tablets (1 g) per reception up to 3 times a day. The minimum interval between doses should be 4 hours.

    The maximum daily dose should not exceed 3 g (6 tablets).

    Aged people:

    1 tablet (500 mg) per reception up to 4 times a day.

    With severe pain and high temperature - 2 tablets (1 g) per reception.

    The minimum interval between doses should be 4 hours.

    The maximum daily dose should not exceed 2 g (4 tablets).

    Duration of treatment (without consulting a doctor) should not exceed 5 days with an appointment as an anesthetic and more than 3 days - as an antipyretic agent.

    Side effects:

    The frequency of side effects is shown in accordance with the following scale:

    very frequent - 1/10 appointments (> 10%);

    frequent - 1/100 appointments (> 1% and <10%);

    infrequent - 1/1000 appointments (> 0.1% and <1%);

    rare 1/10 000 prescriptions (> 0.01% and <0.1%);

    very rare - 1/10 000 (<0.01%).

    From the gastrointestinal tract:

    Rarely: nausea, vomiting, epigastric pain, diarrhea (diarrhea), gastrointestinal bleeding (vomiting like "coffee grounds", black "tarry" stool); decreased appetite, increased activity of "liver" transaminases, ulcer and perforation of the stomach;

    From the nervous system:

    Rarely: headache, dizziness, decreased severity of hearing, ringing in the ears.

    From the side of the blood and lymphatic system:

    Rarely: hemorrhagic syndrome (epistaxis, bleeding gums, hemorrhagic rash), increased coagulation time. These effects persist for 4-8 days after discontinuation of the drug and should be taken into account in planning subsequent operations for patients.

    From the immune system:

    Rarely: skin rash, bronchospasm, angioedema. Formation on the basis of the hapten mechanism of the "aspirin" triad (combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses, and intolerance to acetylsalicylic acid and pyrazolone preparations);

    From the liver and bile ducts:

    Very rarely: Reye's syndrome (encephalopathy and acute fatty liver dystrophy with acute development of liver failure).

    If any of the side effects indicated in the manual are aggravated, or if you notice any other side effects not listed in the instructions, stop taking the medication immediately and inform the doctor about it.

    Overdose:

    Symptoms: In the initial stage of poisoning, the symptoms of central nervous system excitement, dizziness, severe headache, decreased hearing acuity, visual impairment, nausea, vomiting, increased breathing. Later there comes depression of consciousness up to a coma, a respiratory insufficiency, disturbances vodnoehlektrolitnogo an exchange.

    Treatment: The patient should be hospitalized, induces vomiting or rinsing of the stomach, appoint Activated carbon and laxative and control of acid-base balance. Apply symptomatic treatment; in cases of severe intoxication, it is possible to use hemodialysis.

    Interaction:

    Acetylsalicylic acid increases the toxicity of methotrexate, the effects of narcotic analgesics, other NSAIDs, oral hypoglycemic drugs, heparin, indirect anticoagulants, thrombolytic agents and platelet aggregation inhibitors, sulfonamides (including co-trimoxazole), triiodothyronine; reduces - uricosuric drugs (benzbromarone, sulfinpyrazone), antihypertensive drugs and diuretics (spironolactone, furosemide).

    Glucocorticosteroids,alcohol and alcohol-containing drugs increase the damaging effect on the mucous membrane of the gastrointestinal tract, increase the risk of developing gastrointestinal bleeding.

    Acetylsalicylic acid increases the concentration of digoxin, barbiturates and lithium preparations in blood plasma.

    Antatsida, containing magnesium and / or aluminum hydroxide, slow down and worsen the absorption of acetylsalicylic acid.

    Special instructions:

    When using drugs containing acetylsalicylic acid in acute respiratory infections caused by viral infections, there is a risk of developing Reye's syndrome (encephalopathy and acute fatty liver with acute development of liver failure). Symptoms of Reye's syndrome include prolonged vomiting, acute encephalopathy, and enlargement of the liver.

    Acetylsalicylic acid reduces the excretion of uric acid from the body, which can cause an acute attack of gout in predisposed patients.

    With prolonged use of the drug should periodically conduct a general blood test and analysis of feces for latent blood, monitor the functional state of the liver.Before surgery, to reduce bleeding during surgery and in the post-operation period, you should cancel taking the drug for 5-7 days and inform the doctor.

    Patients who follow a salt-free or low-salt diet should take into account that each tablet contains 388.5 mg (16.9 mEq) of sodium.

    The drug Uppsinin Uppsa® contains aspartame, which is a derivative of phenylalanine, which is dangerous for patients with phenylketonuria.

    Form release / dosage:

    Tablets effervescent 500 mg.

    Packaging:

    For 4 effervescent tablets in a strip of aluminum foil, coated on the inside with polyethylene. On 4 strips together with the instruction for use are placed in a cardboard box.

    Storage conditions:

    In a dry place at a temperature of 15 to 25 ° C.

    Keep out of the reach of children!

    Shelf life:

    3 years.

    Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N011368 / 01
    Date of registration:27.07.2010
    The owner of the registration certificate:Bristol-Myers SquibbBristol-Myers Squibb France
    Manufacturer: & nbsp
    Representation: & nbspBRISTOL-Majers SKVIBB, LLCBRISTOL-Majers SKVIBB, LLCRussia
    Information update date: & nbsp14.05.2012
    Illustrated instructions
      Instructions
      Up